{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:58:51Z","timestamp":1785466731956,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bayer AG Switzerland, Pharmaceuticals Division"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40123-026-01449-3","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:15:31Z","timestamp":1783192531000},"page":"2797-2811","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aflibercept 24-Month Outcomes in Diabetic Macular Edema With and Without Prior Macular Laser Therapy: Data from the Fight Retinal Blindness! Registry"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3740-5748","authenticated-orcid":false,"given":"Luca","family":"Timoceanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7491-9810","authenticated-orcid":false,"given":"Sarah","family":"Steinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-0274","authenticated-orcid":false,"given":"Mark C.","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5431-4991","authenticated-orcid":false,"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"1449_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"N Cheung","year":"2010","unstructured":"Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(09)62124-3.","journal-title":"Lancet"},{"key":"1449_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S2213-8587(16)30052-3","volume":"5","author":"GS Tan","year":"2017","unstructured":"Tan GS, Cheung N, Sim\u00f3 R, et\u00a0al. Diabetic macular oedema. Lancet Diabetes Endocrinol. 2017;5:143\u201355. https:\/\/doi.org\/10.1016\/S2213-8587(16)30052-3.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1449_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau JWY, Rogers SL, Kawasaki R, et\u00a0al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556\u201364. https:\/\/doi.org\/10.2337\/dc11-1909.","journal-title":"Diabetes Care"},{"key":"1449_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2337\/dc16-2641","volume":"40","author":"SD Solomon","year":"2017","unstructured":"Solomon SD, Chew E, Duh EJ, et\u00a0al. Diabetic retinopathy: a position statement by the American diabetes association. Diabetes Care. 2017;40:412\u20138. https:\/\/doi.org\/10.2337\/dc16-2641.","journal-title":"Diabetes Care"},{"key":"1449_CR5","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1056\/NEJMra1909637","volume":"382","author":"LM Jampol","year":"2020","unstructured":"Jampol LM, Glassman AR, Sun J. Evaluation and care of patients with diabetic retinopathy. N Engl J Med. 2020;382:1629\u201337. https:\/\/doi.org\/10.1056\/NEJMra1909637.","journal-title":"N Engl J Med"},{"key":"1449_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.PUB4","author":"G Virgili","year":"2014","unstructured":"Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD007419.PUB4.","journal-title":"Cochrane Database Syst Rev"},{"key":"1449_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/J.SURVOPHTHAL.2016.03.010","volume":"61","author":"DR Lally","year":"2016","unstructured":"Lally DR, Shah CP, Heier JS. Vascular endothelial growth factor and diabetic macular edema. Surv Ophthalmol. 2016;61:759\u201368. https:\/\/doi.org\/10.1016\/J.SURVOPHTHAL.2016.03.010.","journal-title":"Surv Ophthalmol"},{"key":"1449_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et\u00a0al. Guidelines for the management of diabetic macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185\u2013222. https:\/\/doi.org\/10.1159\/000458539.","journal-title":"Ophthalmologica"},{"key":"1449_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.PUB6","volume":"2018","author":"G Virgili","year":"2018","unstructured":"Virgili G, Parravano M, Evans JR, et\u00a0al. Anti\u2010vascular endothelial growth factor for diabetic macular oedema: a network meta\u2010analysis. Cochrane Database Syst Rev. 2018;2018:CD007419. https:\/\/doi.org\/10.1002\/14651858.CD007419.PUB6.","journal-title":"Cochrane Database Syst Rev"},{"key":"1449_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ophtha.2024.12.020","volume":"132","author":"JI Lim","year":"2025","unstructured":"Lim JI, Kim SJ, Bailey ST, et\u00a0al. Diabetic retinopathy preferred practice pattern\u00ae. Ophthalmology. 2025;132:75\u2013162. https:\/\/doi.org\/10.1016\/j.ophtha.2024.12.020.","journal-title":"Ophthalmology"},{"key":"1449_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/J.PRETEYERES.2023.101219","author":"PH Gabrielle","year":"2023","unstructured":"Gabrielle PH, Mehta H, Barthelmes D, et\u00a0al. From randomised controlled trials to real-world data: clinical evidence to guide management of diabetic macular oedema. Prog Retin Eye Res. 2023. https:\/\/doi.org\/10.1016\/J.PRETEYERES.2023.101219.","journal-title":"Prog Retin Eye Res"},{"key":"1449_CR12","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1007\/S12325-022-02326-8","volume":"39","author":"H Mehta","year":"2022","unstructured":"Mehta H, Nguyen V, Barthelmes D, et\u00a0al. Outcomes of over 40,000 eyes treated for diabetic macula Edema in routine clinical practice: a systematic review and meta-analysis. Adv Ther. 2022;39:5376\u201390. https:\/\/doi.org\/10.1007\/S12325-022-02326-8.","journal-title":"Adv Ther"},{"key":"1449_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164782","volume":"13","author":"CC Ma","year":"2024","unstructured":"Ma CC, Chen PH, Hsieh YH. Optimizing diabetic macular Edema treatment: a meta-analysis of subthreshold micropulse laser and anti-vascular endothelial growth factor combination therapy. J Clin Med. 2024;13:4782. https:\/\/doi.org\/10.3390\/jcm13164782.","journal-title":"J Clin Med"},{"key":"1449_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13185439","volume":"13","author":"S Wang","year":"2024","unstructured":"Wang S, Hua R, Zhao Y, Liu L. Laser treatment for diabetic retinopathy: history, mechanism, and novel technologies. J Clin Med. 2024;13:5439. https:\/\/doi.org\/10.3390\/jcm13185439.","journal-title":"J Clin Med"},{"key":"1449_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010859.PUB2","author":"EC Jorge","year":"2018","unstructured":"Jorge EC, Jorge EN, Botelho M, et\u00a0al. Monotherapy laser photocoagulation for diabetic macular oedema. Cochrane Database Syst Rev. 2018. https:\/\/doi.org\/10.1002\/14651858.CD010859.PUB2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1449_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/IAE.0B013E318296B271","volume":"34","author":"MC Gillies","year":"2014","unstructured":"Gillies MC, Walton R, Liong J, et\u00a0al. Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! project. Retina. 2014;34:188\u201395. https:\/\/doi.org\/10.1097\/IAE.0B013E318296B271.","journal-title":"Retina"},{"key":"1449_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/J.JCLINEPI.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, et\u00a0al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139. https:\/\/doi.org\/10.1016\/J.JCLINEPI.2007.11.008.","journal-title":"J Clin Epidemiol"},{"key":"1449_CR18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/J.OPHTHA.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, et\u00a0al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Ophthalmology. 2016;123:1351\u20139. https:\/\/doi.org\/10.1016\/J.OPHTHA.2016.02.022.","journal-title":"Ophthalmology"},{"issue":"10","key":"1449_CR19","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/J.OPHTHA.2015.06.017","volume":"122","author":"DM Brown","year":"2015","unstructured":"Brown DM, Schmidt-Erfurth U, Do DV, et\u00a0al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2015;122(10):2044\u201352. https:\/\/doi.org\/10.1016\/J.OPHTHA.2015.06.017.","journal-title":"Ophthalmology"},{"key":"1449_CR20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2147\/OPTH.S100764","volume":"10","author":"PU Dugel","year":"2016","unstructured":"Dugel PU, Hillenkamp J, Sivaprasad S, et\u00a0al. Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials. Clin Ophthalmol. 2016;10:1103\u201310. https:\/\/doi.org\/10.2147\/OPTH.S100764.","journal-title":"Clin Ophthalmol"},{"key":"1449_CR21","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1038\/S41433-023-02409-Y","volume":"37","author":"S Sivaprasad","year":"2023","unstructured":"Sivaprasad S, Ghanchi F, Kelly SP, et\u00a0al. Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes. Eye (Lond). 2023;37:2753\u201360. https:\/\/doi.org\/10.1038\/S41433-023-02409-Y.","journal-title":"Eye (Lond)"},{"key":"1449_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40123-023-00829-3","volume":"13","author":"S Donati","year":"2024","unstructured":"Donati S, Yang CH, Xu X, et\u00a0al. Intravitreal aflibercept for the treatment of diabetic macular edema in routine clinical practice: results from the 24-month AURIGA observational study. Ophthalmol Ther. 2024;13:161\u201378. https:\/\/doi.org\/10.1007\/s40123-023-00829-3.","journal-title":"Ophthalmol Ther"},{"key":"1449_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22838-1","volume":"12","author":"JF Korobelnik","year":"2022","unstructured":"Korobelnik JF, Daien V, Faure C, et\u00a0al. Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema. Sci Rep. 2022;12:18242. https:\/\/doi.org\/10.1038\/s41598-022-22838-1.","journal-title":"Sci Rep"},{"key":"1449_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/JAMAOPHTHALMOL.2019.1963","volume":"137","author":"NM Bressler","year":"2019","unstructured":"Bressler NM, Odia I, Maguire M, et\u00a0al. Association between change in visual acuity and change in central subfield thickness during treatment of diabetic macular Edema in participants randomized to aflibercept, bevacizumab, or ranibizumab: a post hoc analysis of the protocol T randomized clinical trial. JAMA Ophthalmol. 2019;137:977\u201385. https:\/\/doi.org\/10.1001\/JAMAOPHTHALMOL.2019.1963.","journal-title":"JAMA Ophthalmol"},{"key":"1449_CR25","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/S41433-019-0522-Z","volume":"34","author":"SR Sadda","year":"2020","unstructured":"Sadda SR, Campbell J, Dugel PU, et\u00a0al. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: a post hoc analysis of Protocol I data. Eye (Lond). 2020;34:480\u201390. https:\/\/doi.org\/10.1038\/S41433-019-0522-Z.","journal-title":"Eye (Lond)"},{"key":"1449_CR26","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/J.OPHTHA.2011.01.031","volume":"118","author":"P Mitchell","year":"2011","unstructured":"Mitchell P, Bandello F, Schmidt-Erfurth U, et\u00a0al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615\u201325. https:\/\/doi.org\/10.1016\/J.OPHTHA.2011.01.031.","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01449-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01449-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01449-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:05:52Z","timestamp":1785463552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01449-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1449"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01449-3","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Professor Mark C Gillies receives research support and is an advisory board member for Novartis, Bayer, Apellis, Astellas, and Roche. Professor Daniel Barthelmes received grants from Novartis (not ongoing). Sarah Steinmann has nothing to disclose. Luca Timoceanu has nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the principles of the Declaration of Helsinki and was approved by the Cantonal Ethics Committee Zurich, Zurich, Switzerland (approval no. PB_2016-00264). Written informed consent was obtained from all participants prior to their inclusion in the Fight Retinal Blindness! Registry.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}